Overview

SNIFF Multi-Device Study 2

Status:
Active, not recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this study will look at the effects of insulin administered intra-nasally on memory, and on blood levels of insulin.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Insulin
Insulin, Globin Zinc
Insulin, Isophane